Repurposed drug extends survival in aggressive ovarian cancer

Relacorilant, a medication usually prescribed to treat Cushing's syndrome, proves effective in extending survival in patients with aggressive ovarian cancer, according to clinical trials.

Published 20sem1 sourceImportant

Lire en français

≈ 23sSpeed

The fact

This therapeutic reorientation demonstrates the value of revisiting existing molecules for new oncological indications.

The results open promising perspectives for improving ovarian cancer treatment protocols.

Click the link to read an article on the topic:

The Guardian Science

Explore this topic

#cancer ovarien #relacorilant #essai clinique #oncologie

What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.

Follow topic →

Auto-synthesis from 1 media source · identified on April 12, 2026

← Back to home

The fact

Read more

Ovarian cancer: Common medication offers unexpected therapeutic lead

Two new treatments show promise in ovarian cancer survival

Resistant ovarian cancer: two promising treatments identified

Breakthrough drug doubles survival rates for pancreatic cancer patients

New drug doubles survival for pancreatic cancer patients

Anticancer drug could address a global health threat